Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Roche’s TIGIT data leak; Regeneron gets important US approvals; COVID subvariant vaccine progress; Pfizer’s RSV vaccine extended approval; and Japan recommends lecanemab for Alzheimer’s.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 25 August 2023, including: Roche Holding AG’s TIGIT data leak; Regeneron Pharmaceuticals, Inc. gets important US approvals; COVID subvariant vaccine progress; Pfizer Inc.’s RSV vaccine extended approval; and Japan recommends lecanemab for Alzheimer’s.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug" - Scrip, 23 Aug, 2023.)
(Also see "UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals" - Scrip, 18 Aug, 2023.)
(Also see "Drug Makers Gear Up For 2023-2024 COVID-19 Season With Subvariant Vaccines" - Scrip, 22 Aug, 2023.)
(Also see "Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants" - Scrip, 21 Aug, 2023.)
(Also see "Japan Committee Recommends Lecanemab Approval" - Scrip, 22 Aug, 2023.)